PATENT CLAIM ANALYSIS

Application Number: 15746806
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-12
Patent Classification: ["514", "04400A"]

Abstract:
The present invention relates to the combination of a PARP inhibitor with a Dbait molecule for treating cancer.

Claim (Index 5):
The pharmaceutical composition according to  claim 1 , wherein the nucleic acid molecule has one of the following formulae: wherein the underlined nucleotide refers to a nucleotide having a phosphorothioate or methylphosphonate backbone, the linked L\u2032 is selected from the group consisting of hexaethyleneglycol, tetradeoxythymidylate (T4), 1,19-bis(phospho)-8-hydraza-2-hydroxy-4-oxa-9-oxo-nonadecane and 2,19-bis(phosphor)-8-hydraza-1-hydroxy-4-oxa-9-oxo-nonadecane; m is 1 and L is a carboxamido oligoethylene glycol, C is selected from the group consisting of single or double chain fatty acids such as octadecyl and dioleoyl, cholesterol, tocopherol, folic acid, sugar such as galactose and mannose and their oligosaccharide, peptide such as RGD and bombesin and protein such as integrin, preferably cholesterol.

Metadata:
- Claim Count in Document: 67.0
- Percentile: 86.0
- Lexical Diversity: 1.05556
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['13703965', '14118583', '15632951', '15232844', '14923482']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8610951333903227
- 35 USC 102 Novelty (BERT): 0.5858916150009446
- Combined Prediction Score: 0.8335747815513849
- Mean Citation Score: 480.07088600000014
- Max Citation Score: 505.55835
- Similarity Product: 448.5005704936624

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test